Cellular and Molecular Effects of Eribulin in Preclinical Models of Hematologic Neoplasms

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Dec 23

PMID 36551566

Authors

Hugo Passos Vicari

Keli Lima

Leticia Veras Costa-Lotufo

Joao Agostinho Machado-Neto

Affiliations

Soon will be listed here.

Abstract

Despite the advances in understanding the biology of hematologic neoplasms which has resulted in the approval of new drugs, the therapeutic options are still scarce for relapsed/refractory patients. Eribulin is a unique microtubule inhibitor that is currently being used in the therapy for metastatic breast cancer and soft tissue tumors. Here, we uncover eribulin's cellular and molecular effects in a molecularly heterogeneous panel of hematologic neoplasms. Eribulin reduced cell viability and clonogenicity and promoted apoptosis and cell cycle arrest. The minimal effects of eribulin observed in the normal leukocytes suggested selectivity for malignant blood cells. In the molecular scenario, eribulin induces DNA damage and apoptosis markers. The , , p-AKT, p-NFκB, and NFκB levels were associated with responsiveness to eribulin in blood cancer cells, and a resistance eribulin-related target score was constructed. Combining eribulin with elacridar (a P-glycoprotein inhibitor), but not with PDTC (an NFkB inhibitor), increases eribulin-induced apoptosis in leukemia cells. In conclusion, our data indicate that eribulin leads to mitotic catastrophe and cell death in blood cancer cells. The expression and activation of MDR1, PI3K/AKT, and the NFκB-related targets may be biomarkers of the eribulin response, and the combined treatment of eribulin and elacridar may overcome drug resistance in these diseases.

Citing Articles

Eribulin exerts multitarget antineoplastic activity in glioma cells.

Alcantara G, do Nascimento M, de Miranda L, de Almeida B, Lima K, Rego E Pharmacol Rep. 2025; .

PMID: 40056292 DOI: 10.1007/s43440-025-00711-y.

Eribulin induces micronuclei and enhances the nuclear localization of cGAS in triple-negative breast cancer cells.

Yamada H, Takada M, Ghone D, Yu M, Nagashima T, Fujimoto H Res Sq. 2023; .

PMID: 38106033 PMC: 10723555. DOI: 10.21203/rs.3.rs-3672056/v1.

Suppression of alpha-tubulin acetylation potentiates therapeutic efficacy of Eribulin in liver cancer.

Zhong Y, Wang C, Wang Y, Wu Y, Wang H, Qiu S Am J Cancer Res. 2023; 13(11):5698-5718.

PMID: 38058833 PMC: 10695797.

References

Kavallaris M, Tait A, Walsh B, He L, Horwitz S, Norris M . Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res. 2001; 61(15):5803-9. View

cermak V, Dostal V, Jelinek M, Libusova L, Kovar J, Rosel D . Microtubule-targeting agents and their impact on cancer treatment. Eur J Cell Biol. 2020; 99(4):151075. DOI: 10.1016/j.ejcb.2020.151075. View

Szakacs G, Paterson J, Ludwig J, Booth-Genthe C, Gottesman M . Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5(3):219-34. DOI: 10.1038/nrd1984. View

Jordan M, Kamath K, Manna T, Okouneva T, Miller H, Davis C . The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005; 4(7):1086-95. DOI: 10.1158/1535-7163.MCT-04-0345. View

Yahiro K, Matsumoto Y, Fukushi J, Kawaguchi K, Endo M, Setsu N . Class III -Tubulin Overexpression Induces Chemoresistance to Eribulin in a Leiomyosarcoma Cell Line. Anal Cell Pathol (Amst). 2018; 2018:8987568. PMC: 6033248. DOI: 10.1155/2018/8987568. View

Towle M, Salvato K, Budrow J, Wels B, Kuznetsov G, Aalfs K . In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001; 61(3):1013-21. View

Cragg G . Paclitaxel (Taxol): a success story with valuable lessons for natural product drug discovery and development. Med Res Rev. 1998; 18(5):315-31. DOI: 10.1002/(sici)1098-1128(199809)18:5<315::aid-med3>3.0.co;2-w. View

Liaw T, Chang M, Kavallaris M . The cytoskeleton as a therapeutic target in childhood acute leukemia: obstacles and opportunities. Curr Drug Targets. 2007; 8(6):739-49. DOI: 10.2174/138945007780830836. View

Martini M, De Santis M, Braccini L, Gulluni F, Hirsch E . PI3K/AKT signaling pathway and cancer: an updated review. Ann Med. 2014; 46(6):372-83. DOI: 10.3109/07853890.2014.912836. View

10.

Nabekura T, Kawasaki T, Jimura M, Mizuno K, Uwai Y . Microtubule-targeting anticancer drug eribulin induces drug efflux transporter P-glycoprotein. Biochem Biophys Rep. 2020; 21:100727. PMC: 6976863. DOI: 10.1016/j.bbrep.2020.100727. View

11.

Omori M, Noro R, Seike M, Matsuda K, Hirao M, Fukuizumi A . Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer. Thorac Cancer. 2022; 13(15):2142-2151. PMC: 9346178. DOI: 10.1111/1759-7714.14527. View

12.

Zheng W, Seletsky B, Palme M, Lydon P, Singer L, Chase C . Macrocyclic ketone analogues of halichondrin B. Bioorg Med Chem Lett. 2004; 14(22):5551-4. DOI: 10.1016/j.bmcl.2004.08.069. View

13.

Zelnak A . Clinical pharmacology and use of microtubule-targeting agents in cancer therapy. Methods Mol Med. 2007; 137:209-34. DOI: 10.1007/978-1-59745-442-1_15. View

14.

Bar-Zeev M, Kelmansky D, Assaraf Y, Livney Y . β-Casein micelles for oral delivery of SN-38 and elacridar to overcome BCRP-mediated multidrug resistance in gastric cancer. Eur J Pharm Biopharm. 2018; 133:240-249. DOI: 10.1016/j.ejpb.2018.10.018. View

15.

Smith J, Wilson L, Azarenko O, Zhu X, Lewis B, Littlefield B . Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry. 2009; 49(6):1331-7. PMC: 2846717. DOI: 10.1021/bi901810u. View

16.

Ikeda D, Chi S, Uchiyama S, Nakamura H, Guo Y, Yamauchi N . Molecular Classification and Overcoming Therapy Resistance for Acute Myeloid Leukemia with Adverse Genetic Factors. Int J Mol Sci. 2022; 23(11). PMC: 9180585. DOI: 10.3390/ijms23115950. View

17.

Forte D, Salvestrini V, Corradi G, Rossi L, Catani L, Lemoli R . The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling. Oncotarget. 2016; 8(2):2261-2274. PMC: 5356797. DOI: 10.18632/oncotarget.13664. View

18.

Kuznetsov G, Towle M, Cheng H, Kawamura T, TenDyke K, Liu D . Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res. 2004; 64(16):5760-6. DOI: 10.1158/0008-5472.CAN-04-1169. View

19.

Park Y, Son J, Lee B, Kim H, Yoon S . Highly Eribulin-resistant KBV20C Oral Cancer Cells Can Be Sensitized by Co-treatment with the Third-generation P-Glycoprotein Inhibitor, Elacridar, at a Low Dose. Anticancer Res. 2017; 37(8):4139-4146. DOI: 10.21873/anticanres.11801. View

20.

Lai T, Fang C, Jan Y, Hsieh H, Yang Y, Liu C . Kinase shRNA screening reveals that TAOK3 enhances microtubule-targeted drug resistance of breast cancer cells via the NF-κB signaling pathway. Cell Commun Signal. 2020; 18(1):164. PMC: 7579951. DOI: 10.1186/s12964-020-00600-2. View